JPMorgan Chase & Co. Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €59.40 Price Target

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €59.40 ($69.07) price objective by analysts at JPMorgan Chase & Co. in a report issued on Tuesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 23.29% from the stock’s current price.

Several other equities research analysts have also issued reports on the company. Independent Research set a €51.00 ($59.30) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. HSBC set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Deutsche Bank set a €65.00 ($75.58) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Sanford C. Bernstein set a €52.00 ($60.47) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research note on Tuesday, November 12th. Finally, Goldman Sachs Group set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Fresenius SE & Co KGaA currently has a consensus rating of “Buy” and a consensus price target of €55.37 ($64.38).

Shares of FRE stock opened at €48.18 ($56.02) on Tuesday. The business has a 50-day moving average price of €49.83 and a two-hundred day moving average price of €46.34. Fresenius SE & Co KGaA has a 12-month low of €60.16 ($69.95) and a 12-month high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: Pattern Day Trader – What is the PDT Rule?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.